Mechanism of action<unk>  is a gonadotropin-releasing hormone (GnRH) analogue acting as an agonist at pituitary GnRH receptors. Agonism of GnRH receptors initially results in the stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion by the anterior pituitary ultimately leading to increased serum estradiol and testosterone levels via the normal physiology of the hypothalamic–pituitary–gonadal axis (HPG axis); however, because propagation of the HPG axis is incumbent upon pulsatile hypothalamic GnRH secretion, pituitary GnRH receptors become desensitised after several weeks of continuous<unk>  therapy. This protracted downregulation of GnRH receptor activity is the targeted objective of<unk>  therapy and ultimately results in decreased LH and FSH secretion, leading to hypogonadism and thus a dramatic reduction in estradiol and testosterone levels regardless of sex. In the treatment of prostate cancer, the initial increase in testosterone levels associated with the initiation of<unk>  therapy is counterproductive to treatment goals. This effect is avoided with concurrent utilisation of 5α-reductase inhibitors, such as finasteride, or flutamide which function to block the downstream effects of testosterone. Available forms<unk>  is available in the following forms, among others: * Short-acting daily intramuscular injection (Lupron) * Long-acting depot intramuscular injection (Lupron Depot) * Long-acting depot subcutaneous injection (Eligard) * Long-acting subcutaneous injection (Fensolvi) * Long-acting subcutaneous implant (Viadur) * Long-acting leuprolide mesylate (Camcevi) for the treatment of advanced prostate cancer. * Leuprolide acetate and norethindrone acetate combination pack (Lupaneta Pack)
Leuprorelin
Fertirelin
Protollin
Macimorelin
Lumacaftor
Tesamorelin
Octreotide
Gonadorelin